


## Elucidating the structure-activity relationship of the pentaglutamic acid sequence of minigastrin with the cholecystokinin receptor subtype 2

A. Ritler<sup>1,4</sup>, X. Deupi<sup>2</sup>, H. Wennemers<sup>3</sup>, R. Schibli<sup>4,1</sup>, M. Béhé<sup>4\*</sup>

<sup>1</sup>Department of Chemistry and Applied Biosciences (D-CHAB), Institute of Pharmaceutical Sciences (IPW), ETH Zurich, <sup>2</sup>Laboratory of Biomolecular Research, and Condensed Matter Theory Group, Paul Scherrer Institute (Switzerland), <sup>3</sup>Department of Chemistry and Applied Biosciences (D-CHAB), Laboratory of Organic Chemistry (LOC), ETH Zurich, <sup>4</sup>Research Department Biology and Chemistry, Center for Radiopharmaceutical Sciences (CRS), Paul Scherrer Institute (Switzerland)

Radiolabelled minigastrin derivatives are used to target the cholecystokinin receptor subtype 2 (CCK2R) which is overexpressed on neuroendocrine tumors.<sup>[1]</sup> Binding behavior as well as undesired kidney uptake are influenced by the pentaglutamic acid sequence of minigastrin, but the interactions and structural influences on a molecular level are not fully understood. We replaced the pentaglutamic acid sequence in minigastrin with linkers differing in their structural features, their flexibility and the number of anionic charges in order to elucidate the structure-activity relationship of this sequence with the CCK2R. Specifically, a flexible aliphatic linker, a linker with only three D-Glu residues and a structured linker with four adjacent  $\beta^3$ -glutamic acid residues were evaluated and compared to the lead compound PP-F11N (DOTA-[D-Glu<sup>1-6</sup>, Nle<sup>11</sup>]gastrin-13). The minigastrin derivatives were conjugated to 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA), which allowed radiolabelling with <sup>177</sup>Lutetium. The radiolabelled ligands were examined for their *in vitro* properties (IC<sub>50</sub>, internalization and serum stability) and for their *in vivo* behavior in tumor bearing mice with a human medullary thyroid cancer cell line (MZ-CRC1). Structural features of the ligands were evaluated by molecular modelling and CD-spectroscopy.



The obtained IC<sub>50</sub> values are in the low nanomolar range (15-35 nM), with the aliphatic elongated peptide as the only exception with almost one order of magnitude higher values (>100 nM). *In vitro* internalization into MZ-CRC1 cells and *in vivo* tumor uptake, as well as human blood plasma stability increased in the following order: no linker, aliphatic sequence, (D-Glu)<sub>3</sub> sequence, ( $\beta^3$ -Glu)<sub>4</sub> sequence, (D-Glu)<sub>6</sub> sequence. The tumor uptake was dependent on the amount of anionic charges and structural features present. We envision that correlating the observed biological properties with structural features will lead to a better understanding of the molecular structural binding behaviour of peptidic CCK2R ligands which enables an improved rational design of such ligands.

[1] Laverman, et al., *European Journal of Nuclear Medicine and Molecular Imaging* **2011**, 38 (8), 1410-1416.